Gene · 6755
SSTR5: somatostatin receptor 5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. SSTR5: somatostatin receptor 5. Genes, record 6755. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/6755
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35346 | Somatostatin receptor type 5 | 364 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents63
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 64918 | P35346 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 64919 | P35346 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 4458 | P35346 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 4458 | P35346 | Espacenet |
| US 12121590 B2 | 2024-10-22 | 123 | P35346 | Espacenet |
| US 11701430 B2 | 2023-07-18 | 123 | P35346 | Espacenet |
| US 11541119 B2 | 2023-01-03 | 20 | P35346 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 82337 | P35346 | Espacenet |
| US 11400116 B2 | 2022-08-02 | 937 | P35346 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 185308 | P35346 | Espacenet |
1 to 10 of 63
See all 63 patentsDrugs13
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| LANREOTIDE | CHEMBL1201185 | Somatostatin receptor 5 agonist | AGONIST | ChEMBL |
| LANREOTIDE ACETATE | CHEMBL1201184 | Somatostatin receptor 5 agonist | AGONIST | ChEMBL |
| LUTETIUM OXODOTREOTIDE | CHEMBL4302409 | Somatostatin receptor binding agent | BINDING AGENT | ChEMBL |
| LUTETIUM OXODOTREOTIDE LU-177 | CHEMBL4297545 | Somatostatin receptor binding agent | BINDING AGENT | ChEMBL |
| OCTREOTIDE | CHEMBL1680 | Somatostatin receptor agonist | AGONIST | ChEMBL |
| OCTREOTIDE ACETATE | CHEMBL1200480 | Somatostatin receptor agonist | AGONIST | ChEMBL |
| ONZIGOLIDE | CHEMBL4650342 | Somatostatin receptor 5 agonist | AGONIST | ChEMBL |
| PASIREOTIDE | CHEMBL3349607 | Somatostatin receptor 5 agonist | AGONIST | ChEMBL |
| PASIREOTIDE DIASPARTATE | CHEMBL5314380 | Somatostatin receptor 5 agonist | AGONIST | ChEMBL |
| PASIREOTIDE PAMOATE | CHEMBL5314382 | Somatostatin receptor 5 agonist | AGONIST | ChEMBL |
1 to 10 of 13
See all 13 drugsTrials390
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07595237 | LUTETIUM OXODOTREOTIDE LU-177 | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07583563 | OCTREOTIDE | ClinicalTrials.gov | ||
| NCT07537010 | LUTETIUM OXODOTREOTIDE LU-177 | PHASE1 | ClinicalTrials.gov | |
| NCT07534371 | SOMATOSTATIN | ClinicalTrials.gov | ||
| NCT07460908 | OCTREOTIDE | ClinicalTrials.gov | ||
| NCT07316686 | LUTETIUM OXODOTREOTIDE LU-177 | PHASE1 | ClinicalTrials.gov | |
| NCT07304466 | SOMATOSTATIN | ClinicalTrials.gov | ||
| NCT07252401 | SOMATOSTATIN | ClinicalTrials.gov | ||
| NCT07229768 | LUTETIUM OXODOTREOTIDE LU-177 | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07189871 | LUTETIUM OXODOTREOTIDE LU-177 | PHASE1/PHASE2 | ClinicalTrials.gov |
1 to 10 of 390
See all 390 trialsNIH grants448
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | SSTR5 papers | Newest fiscal year |
|---|---|---|---|
| P30CA008748 | Cancer Center Support Grant | 7 | 2025 |
| P30CA086862 | Cancer Center Support Grant | 5 | 2025 |
| P30DK084567 | Mayo Center for Cell Signaling in Gastroenterology | 4 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 3 | 2025 |
| R01DA008863 | Regulation Of Opioid Receptor Signaling by Endogenous Peptides | 3 | 2025 |
| K12CA086913 | Paul Calabresi Award in Clinical Oncology Research | 2 | 2025 |
| P30CA013148 | Comprehensive Cancer Center Support Grant | 2 | 2025 |
| P30CA023074 | University of Arizona Cancer Center - Cancer Center Support Grant | 2 | 2025 |
| R01CA134675 | Enhanced imaging and treatment of aggressive subtypes of prostate cancer | 2 | 2025 |
| ZIADK053200 | Diagnosis, Natural History, Management, tumor biology of Gastrinomas/PETs/Neuroendocrine tumors | 2 | 2025 |
1 to 10 of 448Source NIH's project files
See all 448 nih grantsPapers1,882
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Predictors of in vitro response to somatostatin and dopamine receptor-targeted treatments are lacking in clinically non-functioning pituitary tumors. | J Neuroendocrinol | 2026 | 42785810 | PubTator, text mining | PubMed |
| Tirzepatide for pasireotide-induced hyperglycemia in a GH/TSH-producing pituitary adenoma/PitNET: a case report and literature review. | Endocr J | 2026 | 42732962 | PubTator, text mining | PubMed |
| Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation. | Front Endocrinol (Lausanne) | 2026 | 42723843 | PubTator, text mining | PubMed |
| Microbiota contributes to regulates the external genitalia development through gut-testis axis in male geese. | Poult Sci | 2026 | 42617270 | PubTator, text mining | PubMed |
| Multi-omics integration unravels four molecular subgroups of corticotroph pituitary neuroendocrine tumours with distinct clinicopathological features. | Nat Commun | 2026 | 42552318 | PubTator, text mining | PubMed |
| Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1-5 and Therapeutic Implications in Neuroendocrine and Non-Neuroendocrine Malignancies. | Int J Cancer | 2026 | 42400125 | PubTator, text mining | PubMed |
| Expression of ATRX, DAXX, PDX1, ARX, and somatostatin receptors in pancreatic neuroendocrine tumors: a clinicopathological study. | Front Endocrinol (Lausanne) | 2026 | 42199802 | PubTator, text mining | PubMed |
| Structural and Functional Basis of SSTR5 Homodimerization in Controlling Receptor Signaling and Pasireotide Response in Corticotroph Adenomas. | FASEB J | 2026 | 42141916 | PubTator, text mining | PubMed |
| Somatostatin and Its Analogues as Second-Line Treatments in Non-Neoplastic Conditions. | Int J Mol Sci | 2026 | 42123401 | PubTator, text mining | PubMed |
| Impact of Neuroendocrine Neoplasm-Specific Systemic Treatments on Somatostatin Receptors Expression and Function in Neuroendocrine Tumor Cells. | Cancers (Basel) | 2026 | 42122164 | PubTator, text mining | PubMed |
1 to 10 of 1,882
See all 1,882 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/6755
GET https://conductscience.org/api/genes/v1/6755/patents?page=2